Biomarkers in Severe Asthma
- PMID: 27401625
- PMCID: PMC6057475
- DOI: 10.1016/j.iac.2016.03.004
Biomarkers in Severe Asthma
Abstract
Biomarkers have been critical for studies of disease pathogenesis and the development of new therapies in severe asthma. In particular, biomarkers of type 2 inflammation have proven valuable for endotyping and targeting new biological agents. Because of these successes in understanding and marking type 2 inflammation, lack of knowledge regarding non-type 2 inflammatory mechanisms in asthma will soon be the major obstacle to the development of new treatments and management strategies in severe asthma. Biomarkers can play a role in these investigations as well by providing insight into the underlying biology in human studies of patients with severe asthma.
Keywords: Biomarker; Endotype; Eosinophil; Exhaled nitric oxide; Periostin; Severe asthma.
Copyright © 2016 Elsevier Inc. All rights reserved.
References
-
- Biomarkers Definitions Working Group. Biomarkers and surrogate endpoints: preferred definitions and conceptual framework. Clin Pharmacol Ther. 2001;69(3):89–95. - PubMed
-
- Reddel HK, Taylor DR, Bateman ED, et al. An official American Thoracic Society/European Respiratory Society Statement: asthma control and exacerbations. Am J Respir Crit Care Med. 2009;180(1):59–99. - PubMed
-
- Belda J, Leigh R, Parameswaran K, et al. Induced sputum cell counts in healthy adults. Am J Respir Crit Care Med. 2000;161(2 Pt 1):475–8. - PubMed
-
- Spanevello A, Confalonieri M, Sulotto F, et al. Induced sputum cellularity. Am J Respir Crit Care Med. 2000;162(3):1172–4. - PubMed
-
- Pizzichini E, Pizzichini MM, Efthimiadis A, et al. Indices of airway inflammation in induced sputum: reproducibility and validity of cell and fluid-phase measurements. Am J Respir Crit Care Med. 1996;154(2 Pt 1):308–17. - PubMed
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical